Starpharma signs license for a VivaGel® condom in China

Jul 21st, 2016

Melbourne, Australia; 21 July 2016: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced the signing of an exclusive license and supply agreement with Shenyang Sky and Land Latex Co. Ltd. (Sky and Land) for the manufacture and sale of VivaGel® condoms to the Government segment of the Chinese condom market. 

Read More

Appendix 4C - Quarterly Cashflow Report

Jul 14th, 2016

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 June 2016.

Read More

Starpharma’s DEP™ eliminates cabazitaxel neutropenia

May 25th, 2016

Melbourne, Australia; 25 May 2016: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that Starpharma’s DEP™ cabazitaxel eliminated neutropenia typical of cabazitaxel (Jevtana®) in a preclinical study. 

Read More

The Conversation: Antiviral condoms will help protect Australian Olympians from STIs – here’s how

May 17th, 2016

The Conversation noted Dual Protect™ anti-viral condoms, which are coated with Starpharma’s VivaGel®, provide an extra level of protection over regular condoms for Australia athletes when they are at the Olympics in Rio. 

Go to the article (external link)

Read More

Starpharma to present at ASX CEO Session

May 17th, 2016

Starpharma is presenting today at The CEO Session Series event in Sydney.

Read More

Australian Olympic Team taking Dual Protect™ VivaGel® Condoms to Rio

May 16th, 2016

Starpharma and Ansell today proudly announce that the Australian Olympic team will be provided with antiviral Dual Protect™ VivaGel® condoms for the upcoming Olympic Games in Rio de Janeiro.

Read More

VivaGel® active against Zika virus

May 5th, 2016

Starpharma announced today that the VivaGel® active, astodrimer sodium (SPL7013), has been shown to have potent antiviral activity against the Zika virus in laboratory studies. The studies showed near complete antiviral protection at SPL7013 concentrations significantly below that used in the VivaGel® condom.

Read More

Appendix 4C - Quarterly Cashflow Report

Apr 28th, 2016

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 March 2016.

Read More

Shareholder Update April 2016

Apr 13th, 2016

In this issue:

> Message from the CEO

> Adama licenses Priostar® for 2,4-D

> DEPTM cabazitaxel shows superior performance

> Starpharma's Targeted DEPTM conjugates - compelling results in an area of high interest

> AstraZeneca selects second DEPTM candidate

> Starpharma long standing collaborator ranked 4th in the world

> Starpharma signs licence with Aspen for commercialisation of VivaGel® BV in Australia and New Zealand

> MOU for VivaGel® condom in China

> Half-year financial results

> Bio-Europe® conference

Download: Shareholder Update April 2016 (pdf file, 1MB)

 

Read More

Starpharma to present at Bio-Europe conference

Apr 5th, 2016

Starpharma today announced that it will present this week at the Bio-Europe® conference in Stockholm. At the conference Starpharma will also be conducting partnering discussions with pharmaceutical companies for VivaGel® BV, DEPTM and other parts of Starpharma’s portfolio.

Read More

DEP cabazitaxel shows complete and sustained tumour regression in breast cancer model

Apr 4th, 2016

Starpharma today announced further efficacy results of its most recent DEP™ candidate, DEP™ cabazitaxel, in a human breast cancer model. These data will be presented along with an overview of Starpharma’s DEP™ platform at the BioEurope Spring 2016 conference in Stockholm later this week.

Read More

Adama Licenses Starpharma's Priostar for Novel 2,4-D

Mar 17th, 2016

Starpharma and Adama today announced the licensing by Adama of Starpharma's Priostar® dendrimer technology for the development and commercialization of an enhanced, proprietary 2,4-D herbicide for the US market. 2,4-D is one of the top three herbicides sold world-wide, with global sales in 2014 estimated by Phillips McDougall to be around US$680 million. The US market in 2014 was worth approximately US$115 million, and has been projected by the US Department of Agriculture to grow by more than 70% by 2020.  

Read More